• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Harrow Launches Harrow Access for All (HAFA)

    9/25/25 4:05:00 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HROW alert in real time by email

    HAFA to Expand Harrow's Innovative Market Access Model Across Ophthalmic Portfolio

    Program will be available in late 2025 through the HarrowAccess.com Portal

    NASHVILLE, Tenn., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of Harrow Access for All ("HAFA"), expanding Harrow's commitment to make it easier and more affordable for patients to access Harrow's full range of branded, generic, and compounded ophthalmic medications. HAFA builds on the success of the VEVYE® Access for All ("VAFA") initiative, which launched in March 2025 with a strong reception from both physicians and patients.

    VAFA was designed to improve access and affordability to VEVYE® (cyclosporine ophthalmic solution) 0.1%, a prescription medication indicated for the treatment of the signs and symptoms of dry eye disease. By addressing cost and administrative barriers, VAFA quickly demonstrated the benefits of a patient-first, patient-focused access model, with VEVYE prescriptions growing 66% in the second quarter of 2025.

    HAFA now expands this proprietary patient access model from a single product to encompass Harrow's comprehensive ophthalmic portfolio of branded, authorized generics (AGx), and compounded ophthalmic medications. Beginning in late 2025 and expanding into 2027, HAFA will provide a single, unified access point for prescribers and patients, offering affordability, streamlined prescribing, and predictable access. The platform creates a simpler, more predictable path to treatment—supporting better outcomes for patients and greater efficiency for physicians.

    "The launch of HAFA is the culmination of five years of work, which began in 2019 as we expanded beyond our market-leading ImprimisRx brand of compounded products, adding a portfolio of more than 15 branded ophthalmic products. We have always believed that our primary job is to serve eyecare professionals and provide what they need to offer optimal care for their patients. In line with this belief, HAFA will serve as the ‘Amazon for Ophthalmology' – a seamless and unified platform, offering white-glove service that allows physicians to focus on patient care rather than managing paperwork, and dealing with pharmacy and pharmaceutical issues," said Mark L. Baum, Chief Executive Officer of Harrow. "As a company committed to reducing access barriers in the ophthalmic space, we recognize that affordability and ease of access are key components of being innovative. HAFA is designed to remove the financial and logistical obstacles that too often prevent patients from receiving timely access. Our goal is to ensure that every patient, regardless of insurance status or financial means, can access our sight-preserving medications without delay."

    Baum continued, "With the launch of HAFA, Harrow reaffirms its role not only as a leader in ophthalmic innovation, but as a dedicated advocate for patient access and affordability. HAFA is an investment in our business, our customers, our healthcare partners, and most of all, in the patients we serve every day."

    HAFA Program Highlights:

    • Predictable, Affordable Pricing
      • Eligible commercially insured patients may pay as little as $0, with out-of-pocket costs for all eligible patients capped at $59, ensuring treatment affordability regardless of coverage status.
    • The HAFA program will be implemented in three phases:
      • Phase 1 (Q4 2025 Launch Expected): Covers the majority of Harrow's specialty product portfolio, including the upcoming launch of BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05%. Eligible patients will pay as little as $0 and no more than $59 out-of-pocket, significantly improving affordability while driving early adoption.
      • Phase 2 (First Half of 2026 Launch Expected): Covers the majority of Harrow's specialty product portfolio, and will include an expanded portfolio of AGx offerings, ensuring continued and improved patient access.
      • Phase 3 (2027 Launch Expected): HAFA will ultimately extend across Harrow's full portfolio of specialty, AGx, and compounded medicines. For eligible patients not covered by insurance, the program ensures uninterrupted access by offering an AGx or affordable cash-pay options, depending on the product, with compounded medication alternatives available as appropriate for the individual patients—guaranteeing that every patient can receive the medication they need.
    • Streamlined HarrowAccess.com Portal

      • HAFA will incorporate a unique centralized portal that transforms the prescribing process into a seamless, hassle-free experience for both physicians and patients.
      • The HarrowAccess.com portal will offer access to Harrow's portfolio of specialty, generic, and compounded ophthalmic medications and Harrow-affiliated partner products.
      • Prescribers will be able to create protocol decision trees for their practice and ensure that patients are able to access the most appropriate medication, approved by their doctor, based on an individual's coverage circumstances.
      • This technology is built to streamline prior authorizations and reduce administrative burden, helping prescribers save time, provide visibility, and improve efficiency.
      • The platform gives physicians an all-in-one solution to manage prescriptions—enabling them to prescribe, refill, track, and respond to patient needs with greater efficiency.

    "My top priority is ensuring that patients have access to the treatments they need without unnecessary barriers. My experience with the launch of VAFA has been a game-changer in this regard. It's remarkably straightforward for both physicians and patients to navigate, reducing administrative burden and accelerating time to therapy," said Dr. Ivan Mac, M.D., a board-certified ophthalmologist and founder of Metrolina Eye Associates in Matthews, NC. "Most importantly, it enables more of my patients, regardless of their insurance status, to access VEVYE or any of the Harrow products – with confidence. It's reassuring to know that we have a program that truly puts patients first, and I am grateful that Harrow has extended this initiative through HAFA to their broad portfolio of Ophthalmic medicines."

    "Access and affordability remain two of the most significant obstacles we face in relation to prescription medications as we seek to deliver consistent, high quality eyecare that improves patient outcomes," said Dr. Cory Lappin, O.D., M.S., F.A.A.O., an Optometrist at the Dry Eye Center of Ohio in Cincinnati, OH. "HAFA directly tackles these challenges by streamlining the path from prescription to treatment while also making medications significantly more affordable for patients. This is the kind of patient-centered approach our industry has needed for years."

    All medications under the HAFA program are dispensed through PhilRx, Harrow's specialty pharmacy partner, with convenient home delivery. Prescriptions are integrated directly through providers' EMR systems, so patients automatically receive HAFA benefits – no copay cards, no extra steps.

    About Harrow

    Harrow, Inc. (NASDAQ: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com.

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks, including litigation matters, and other uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow's filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2024, subsequent Quarterly Reports on Form 10-Q, and other filings with the SEC. Such documents may be read free of charge on the SEC's web site at sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

    Contacts:

    Investors: Media:
    Mike Biega Silvana Guerci-Lena
    VP of Investor Relations & Communications Powers & Company
    [email protected] [email protected]
    617-913-8890 508-808-8993


    Primary Logo

    Get the next $HROW alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HROW

    DatePrice TargetRatingAnalyst
    7/11/2025$76.00Overweight
    Cantor Fitzgerald
    6/12/2025$62.00Buy
    BTIG Research
    6/10/2025Outperform
    William Blair
    2/6/2025$57.00Buy
    H.C. Wainwright
    12/4/2024$73.00 → $69.00Buy
    B. Riley Securities
    4/11/2024$24.00Buy
    Craig Hallum
    9/8/2022$17.00Buy
    B. Riley Securities
    10/14/2021$16.00Buy
    B. Riley Securities
    More analyst ratings

    $HROW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Harrow with a new price target

    Cantor Fitzgerald initiated coverage of Harrow with a rating of Overweight and set a new price target of $76.00

    7/11/25 8:12:59 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Harrow with a new price target

    BTIG Research initiated coverage of Harrow with a rating of Buy and set a new price target of $62.00

    6/12/25 7:54:43 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Harrow

    William Blair initiated coverage of Harrow with a rating of Outperform

    6/10/25 8:09:06 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Harrow to Acquire Melt Pharmaceuticals

    NASHVILLE, Tenn., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into an agreement to acquire Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and in-office settings. The closing of this acquisition is subject to customary closing conditions, including approval by Melt stockholders, excluding Harrow and Harrow-affiliated parties. Melt's lead investigational therapy, MELT-300, is a patented, sublingually delivered formulation of a fixed dose o

    9/26/25 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Launches Harrow Access for All (HAFA)

    HAFA to Expand Harrow's Innovative Market Access Model Across Ophthalmic Portfolio Program will be available in late 2025 through the HarrowAccess.com Portal NASHVILLE, Tenn., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of Harrow Access for All ("HAFA"), expanding Harrow's commitment to make it easier and more affordable for patients to access Harrow's full range of branded, generic, and compounded ophthalmic medications. HAFA builds on the success of the VEVYE® Access for All ("VAFA") initiative, which launched in March 2025 with a strong reception from both physician

    9/25/25 4:05:00 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Announces Agenda and Speakers for Investor & Analyst Day

    NASHVILLE, Tenn., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the agenda for its upcoming Investor & Analyst Day on Friday, September 26, from 11:30 a.m. ET to 3 p.m. ET in New York. The event will also be webcast live and instructions for accessing the webcast are below. Harrow's Investor & Analyst Day will include a comprehensive overview of Harrow's business, featuring presentations from the Company's leadership team covering the full scope of Harrow's commercial portfolio, pipeline, and long-term vision. In addition, the program will include presentations from renowned physici

    9/15/25 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Opaleye Management Inc. bought $199,400 worth of shares (20,000 units at $9.97) (SEC Form 4)

    4 - HARROW, INC. (0001360214) (Issuer)

    4/25/24 5:19:24 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opaleye Management Inc. bought $204,640 worth of shares (20,000 units at $10.23) (SEC Form 4)

    4 - HARROW, INC. (0001360214) (Issuer)

    4/24/24 4:40:20 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opaleye Management Inc. bought $310,390 worth of shares (29,400 units at $10.56) (SEC Form 4)

    4 - HARROW, INC. (0001360214) (Issuer)

    4/19/24 6:24:32 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    SEC Filings

    View All

    Amendment: Harrow Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K/A - HARROW, INC. (0001360214) (Filer)

    10/1/25 7:39:13 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - HARROW, INC. (0001360214) (Filer)

    9/29/25 7:00:47 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - HARROW, INC. (0001360214) (Filer)

    9/26/25 4:05:58 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CHIEF ACCOUNTING OFFICER Pollard Randall E.

    4 - HARROW, INC. (0001360214) (Issuer)

    9/9/25 9:07:57 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Pollard Randall E.

    3 - HARROW, INC. (0001360214) (Issuer)

    9/9/25 9:04:56 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Baum Mark L covered exercise/tax liability with 313,338 shares and exercised 600,000 shares at a strike of $7.87, increasing direct ownership by 11% to 2,886,124 units (SEC Form 4)

    4 - HARROW, INC. (0001360214) (Issuer)

    7/23/25 9:10:48 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    Leadership Updates

    Live Leadership Updates

    View All

    Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

    Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Mike Biega has joined Harrow as Vice President of Investor Relations and Communications, succeeding Jamie Webb, Director of Communications and Investor Relations, who recently announced her retirement. Jamie will remain in her role into August to support a smooth and effective transition. "We are excited to welcome Mike to the Harrow Family. His wealth of experience in investor relations and strategic communications will be a tremendous asset as we pursue our objective of becoming the leading U.S. ophthalmic pharmaceutical company," said Mark L. Baum, Chief Executive Officer of Harrow. "I a

    6/18/25 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

    Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined Harrow as Chief Scientific Officer (CSO). With a remarkable career spanning 28 years in life sciences, Dr. Shojaei brings deep expertise in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, including groundbreaking work in anterior and posterior segment ophthalmic indications. Dr. Shojaei most recently served as CSO and Executive Vice President of Clinical Development at AsclepiX Therapeutics, where he spearheaded the development of innovative therapies for neovascular retinal disorders. P

    1/7/25 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial

    Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow's rapidly growing portfolio of branded ophthalmic products. This new role reflects Harrow's commitment to enhancing its leadership structure to support the Company's continued growth. John Saharek, Harrow's Chief Commercial Officer and Chief Executive Officer of ImprimisRx, will continue to oversee Harrow's commercial business, focusing on the day-to-day management of Harrow's market‑leading compounded division. DiPasquale

    5/13/24 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Harrow Inc.

    SC 13G/A - HARROW, INC. (0001360214) (Subject)

    12/5/24 7:08:52 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Harrow Inc.

    SC 13G/A - HARROW, INC. (0001360214) (Subject)

    10/8/24 6:41:41 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Harrow Inc. (Amendment)

    SC 13G/A - HARROW, INC. (0001360214) (Subject)

    2/13/24 5:25:53 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    Financials

    Live finance-specific insights

    View All

    Harrow Announces Second-Quarter 2025 Financial Results

    Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year periodGAAP net income of $5.0 millionAdjusted EBITDA of $17.0 millionCash and cash equivalents of $53.0 million as of June 30, 2025 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the second quarter ended June 30, 2025. The Company also posted its second quarter Letter to Stockholders and corporate presentation to the "Investors" s

    8/11/25 4:01:00 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025

    NASHVILLE, Tenn., July 29, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2025, on Monday, August 11, 2025, after the market close. The Company will also post its second quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, August 12, 2025, to discuss the results and provide a business update. Conference Call InformationParticipants can access the live webcast of Harrow's presentation on the "Investors" page of Harrow'

    7/29/25 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

    Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW), today announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05%. BYQLOVI was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of post-operative inflammation and pain following ocular surgery and is the first new ophthalmic steroid in its class in over 15 years. Harrow expects BYQLOVI to be available in the fourth quarter of 2025. This press release features multimedia. View the full release here: https://www.busin

    6/9/25 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care